Jump to content

Pertuzumab: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
clean up, Replaced: {{FootnotesSmall|resize=100%}} → <references/> using AWB
Deprecating drugbox-mab
Line 1: Line 1:
{{drugbox-mab
{{drugbox |
| type = mab
| image =
| image =
| source = [[Human]]
| source = [[Human]]

Revision as of 05:38, 11 October 2008

Pertuzumab
Monoclonal antibody
Type?
SourceHuman
TargetHER2
Legal status
Legal status

Pertuzumab (also called 2C4, formerly known as Omnitarg) is a monoclonal antibody. The first of its class in a line of agents called "HER dimerization inhibitors". By binding to HER2, it inhibits the dimerization of HER2 with other HER receptors, which is hypothesized to result in slowed tumor growth.[2] Omnitarg is currently being developed by Genentech.

Early clinical trials of pertuzumab in prostate, breast, and ovarian cancers have been met with limited success.[3]

References

[2]

  1. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
  2. ^ a b de Bono, Johann S. (20 January 2007). "Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer". Journal of Clinical Oncology. 25 (3): 257–262. doi:10.1200/JCO.2006.07.0888. PMID 17235043.
  3. ^ Genentech press release - May 15, 2005

Template:Humanizedmonoclonals